Xiaoming Cui
Academy of Military Medical Sciences(CN)
Publications by Year
Research Areas
Pharmacogenetics and Drug Metabolism, Lung Cancer Treatments and Mutations, Viral Infections and Vectors, Vector-borne infectious diseases, Synthesis and biological activity
Most-Cited Works
- → Identifying SARS-CoV-2-related coronaviruses in Malayan pangolins(2020)2,031 cited
- → Capmatinib in MET Exon 14–Mutated or MET -Amplified Non–Small-Cell Lung Cancer(2020)977 cited
- → Synthesis, Structure–Activity Relationships, and in Vivo Efficacy of the Novel Potent and Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor 5-Chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) Currently in Phase 1 and Phase 2 Clinical Trials(2013)408 cited
- → Large-Scale Comparative Analyses of Tick Genomes Elucidate Their Genetic Diversity and Vector Capacities(2020)350 cited
- → Discovery of (1 R ,5 S )- N -[3-Amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]- 3-[2( S )-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]- 6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2( S )-carboxamide (SCH 503034), a Selective, Potent, Orally Bioavailable Hepatitis C Virus NS3 Protease Inhibitor: A Potential Therapeutic Agent for the Treatment of Hepatitis C Infection(2006)278 cited
- → Distribution of Haemaphysalis longicornis and associated pathogens: analysis of pooled data from a China field survey and global published data(2020)173 cited
- → Emergence of human infection with Jingmen tick virus in China: A retrospective study(2019)163 cited
- → Discovery, Preclinical Characterization, and Early Clinical Activity of JDQ443, a Structurally Novel, Potent, and Selective Covalent Oral Inhibitor of KRASG12C(2022)132 cited
- → Development of a Novel in Vitro Model to Predict Hepatic Clearance Using Fresh, Cryopreserved, and Sandwich-Cultured Hepatocytes(2002)130 cited
- → Metavirome of 31 tick species provides a compendium of 1,801 RNA virus genomes(2023)100 cited